India gave a nod to two more vaccines and one pill against coronavirus. These are the two latest addition to the vaccines approved by CDSCO including Corbevax and Covovax.
This anti-viral drug Molnupiravir can only be used in emergencies. Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare gave a nod for the emergency use of the anti-viral drug Molnupiravir.
Presently, six COVID-19 vaccines including Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Zydus Cadila’s ZyCoV-D, Russia’s Sputnik V and US’ Moderna and Johnson and Johnson have received the emergency use authorisation from India’s drug regulator.
India’s first indigenously developed vaccine is CORBEVAX. It is an RBD protein sub-unit vaccine against COVID-19, made by Hyderabad-based firm Biological-E.
COVOVAX is a nanoparticle vaccine, it will be manufactured by Pune-based firm Serum Institute of India.
On the other hand, Molnupiravir is an antiviral drug that will be manufactured by 13 companies for restricted use in India.
This will be under the emergency situation for treatment of adult patients with COVID-19 with a high risk of progression of the disease.
India’s total tally of COVID-19 cases rose to 3,47,99,691 after 6,358 people tested positive for coronavirus infections in a day.
The active coronavirus cases have declined to 75,456, as per the data updated at 8 am. India logged 653 cases of the Omicron variant of COVID-19 across 21 states and UTs so far.
YOU MAY ALSO WATCH:
ALSO READ | Delmicron, twin variant of Omicron and Delta driving infection rates in the US and Europe